Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 94,413,536
  • Shares Outstanding, K 1,259,015
  • Annual Sales, $ 22,449 M
  • Annual Income, $ 5,386 M
  • 60-Month Beta 0.68
  • Price/Sales 4.19
  • Price/Cash Flow 10.23
  • Price/Book 4.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 1.44
  • Number of Estimates 7
  • High Estimate 1.50
  • Low Estimate 1.33
  • Prior Year 1.67
  • Growth Rate Est. (year over year) -13.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.41 +14.13%
on 03/16/20
85.97 -14.49%
on 03/19/20
-0.01 (-0.01%)
since 03/09/20
3-Month
62.23 +18.13%
on 01/21/20
85.97 -14.49%
on 03/19/20
+7.67 (+11.65%)
since 01/09/20
52-Week
60.89 +20.73%
on 10/03/19
85.97 -14.49%
on 03/19/20
+7.42 (+11.23%)
since 04/09/19

Most Recent Stories

More News
Coronavirus Testing, Vaccines & Treatments: What You Should Know

We discuss latest developments in tests, vaccines and therapies for COVID-19.

JNJ : 141.23 (-1.42%)
REGN : 512.96 (+0.12%)
GILD : 73.51 (-1.97%)
MRNA : 31.86 (-1.73%)
ABT : 86.04 (+1.28%)
VHT : 177.74 (+0.91%)
XBI : 83.43 (+1.88%)
Gilead Canada Submits Supplemental New Drug Submission to Health Canada for Descovy® for HIV Pre-Exposure Prophylaxis

-- Submission supported by data from the DISCOVER trial, which evaluated the safety and efficacy of Descovy® compared to Truvada® in people at risk for sexually acquired HIV-1 infection --

GILD : 73.51 (-1.97%)
Gilead Canada Submits Supplemental New Drug Submission to Health Canada for DESCOVY® for HIV Pre-Exposure Prophylaxis

-- Submission supported by data from the DISCOVER trial, which evaluated the safety and efficacy of Descovy® compared to Truvada® in people at risk for sexually acquired HIV-1 infection --

GILD : 73.51 (-1.97%)
Prime Healthcare Participating in Program for Promising COVID-19 Treatment

One of the most promising treatments for COVID-19 is being made available through an expanded access program at Prime Healthcare's Saint Michael's Medical Center in Newark.

GILD : 73.51 (-1.97%)
Gilead Announces $20 Million Philanthropic Fund to Support Nonprofit Organizations Impacted by the COVID-19 Crisis

Gilead Sciences, Inc. (Nasdaq: GILD) announced the creation of the global Gilead CARES (COVID-19 Acute Relief and Emergency Support) Grantee Fund to provide financial support to current grantees facing...

GILD : 73.51 (-1.97%)
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

GILD : 73.51 (-1.97%)
INCY : 86.81 (-1.07%)
IMMU : 19.64 (+6.57%)
ALNY : 116.38 (+4.48%)
AMGN : 218.21 (-0.45%)
FATE : 27.23 (+6.24%)
VIR : 29.50 (+1.37%)
Biotechs Fast Track Repurposing Existing Drugs for COVID-19 Treatments

The search for vaccines and treatments for the global health crises is now focusing on medicines that are presently approved for other ailments. A recent article in the LA Times discussed this issue saying...

MBRX : 1.1300 (-11.02%)
AKER : 5.13 (-13.78%)
ABT : 86.04 (+1.28%)
PSTI : 6.97 (+43.71%)
GILD : 73.51 (-1.97%)
Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress

The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

JNJ : 141.23 (-1.42%)
REGN : 512.96 (+0.12%)
SNY : 45.46 (+0.62%)
RHHBY : 39.7500 (-1.49%)
DVAX : 2.94 (-6.67%)
PFE : 35.39 (+2.28%)
GILD : 73.51 (-1.97%)
INCY : 86.81 (-1.07%)
MRNA : 31.86 (-1.73%)
GSK : 38.88 (+2.10%)
NVS : 84.85 (-0.90%)
AMGN : 218.21 (-0.45%)
NVAX : 17.05 (-0.76%)
TBI : 14.42 (+1.98%)
Gilead Partners Second Genome, Boosts Coronavirus Drug Production

Gilead (GILD) collaborates with Second Genome for inflammatory bowel disease treatments. The company also plans to ramp up production of remdesivir for coronavirus treatment.

JNJ : 141.23 (-1.42%)
REGN : 512.96 (+0.12%)
SNY : 45.46 (+0.62%)
GILD : 73.51 (-1.97%)
Is Pharma the Sector to Bet on in 2020? 2 Big Stocks to Buy

Here we have highlighted two big pharma stocks that may prove to be good buys. Both these stocks carry a Zacks Rank #1 (Strong Buy) and have seen their share price rise this year.

JNJ : 141.23 (-1.42%)
REGN : 512.96 (+0.12%)
SNY : 45.46 (+0.62%)
GILD : 73.51 (-1.97%)
MRNA : 31.86 (-1.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade GILD with:

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

2nd Resistance Point 75.34
1st Resistance Point 74.43
Last Price 73.51
1st Support Level 72.77
2nd Support Level 72.03

See More

52-Week High 85.97
Fibonacci 61.8% 76.39
Last Price 73.51
Fibonacci 50% 73.43
Fibonacci 38.2% 70.47
52-Week Low 60.89

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar